Category: Breaking

HHS Top Lawyer Tells Lilly, Don’t Assume We Endorse Your 340B Policy

The top lawyer at the U.S. Health and Human Services (HHS) department told drug manufacturer Eli Lilly and Co. in a letter dated Sept. 21 and made

HRSA is Investigating Whether Manufacturer Policies to Restrict 340B Pricing at Contract Pharmacies Violates Statute

In a major development, the Health Resources and Services Administration (HRSA) has told 340B Report that it is investigating whether recent manufacturer policies to restrict

After publication, 340B Report received the following comment from Eli Lilly and Co. on its actions that we reported on today:

Report after report shows 340B is not working for patients and needs reform. We support recent executive action on

Kalderos Wants to Give Drug Manufacturers a Way to Pay 340B Rebates in Lieu of Discounts

Prescription drug information technology company Kalderos announced today it is launching a platform called 340B Pay on Sept. 8 “to facilitate 340B discounts

A Message from Publisher and CEO Ted Slafsky: I hope all is well. For now, we have more requests for 340B Report sponsorships than space available. Fortunately, we are creating a new website and newsletter platform that will accommodate our growing

AstraZeneca Raises the Ante in Drug Industry Push Against 340B Contract Pharmacy

Drug manufacturer AstraZeneca today sent letters to 340B covered entities and its wholesale pharmacy contacts telling them that, effective Oct. 1, it